727.02 is a legacy non-billable code used to specify a medical diagnosis of giant cell tumor of tendon sheath. This code was replaced on September 30, 2015 by its ICD-10 equivalent. References found for the code 727.02 in the Index of Diseases and Injuries:
727.02 is a legacy non-billable code used to specify a medical diagnosis of giant cell tumor of tendon sheath. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
ICD coding ICD-10: 9250/1 - giant cell tumor of bone NOS ICD-11: 2F7B & XH4TC2 - neoplasms of uncertain behavior of bone or articular cartilage & giant cell tumor of bone NOS
Histopathology of localized TGCT arising in hand finger. H&E stain. Localized TGCT is sometimes referred to as localized pigmented villonodular synovitis (L-PVNS), giant cell tumor of the tendon sheath (GCT-TS), nodular tenosynovitis, localized nodular tenosynovitis, and L-TGCT. : 1 : 100
A giant cell tumor is a rare, aggressive non-cancerous tumor. It usually develops near a joint at the end of the bone. Most occur in the long bones of the legs and arms. Giant cell tumors most often occur in young adults when skeletal bone growth is complete. The exact cause of giant cell tumors remains unknown.
While giant cell tumors are typically benign (noncancerous), they can grow quickly and destroy bone close to a joint. In rare cases, a giant cell tumor may spread, or metastasize, to the lungs.
Giant cell tumor of the tendon sheath (GCTTS) is the second most common tumor of the hand after ganglion cysts (1,2). It is a slowly growing, usually painless benign lesion of soft tissues. The tumor affects individuals between the age of 30 and 50 years old and is found more often in women than men (3–6).
D21. 9 is a billable/specific ICD-10-CM code that can be used to indicate a diagnosis for reimbursement purposes. The 2022 edition of ICD-10-CM D21. 9 became effective on October 1, 2021.
Is a giant cell tumor a sarcoma? No. Both giant cell tumors and sarcomas are growths in your bones or soft tissues. Sarcomas are cancer, and GCTs aren't.
Background: Primary and recurrent giant cell tumor of bone is typically benign; however, rarely giant cell tumor of bone can undergo malignant transformation.
Often, partial excision of the joint capsule or tendon sheath is necessary for complete removal of the tumor. Meticulous dissection and exploration are essential because satellite lesions are common.
A tendon sheath is a layer membrane that covers a tendon. Tendons are fibrous tissue that connects muscle to bone. These tumors cause the affected synovium, bursae or tendon sheaths to thicken and overgrow. They are benign, which means they are not cancerous and do not spread to other areas of the body (metastasize).
A giant cell (aka multinucleated giant cell, multinucleate giant cell) is a mass formed by the union of several distinct cells (usually histiocytes), often forming a granuloma.
Listen to pronunciation. (GRAN-yoo-lur sel TOO-mer) A rare type of soft tissue tumor that usually begins in Schwann cells (cells that hold nerve cells in place). It can occur anywhere in the body, but it usually occurs in or under the skin of the head and neck (especially the mouth or tongue).
Malignant neoplasm of connective and soft tissue, unspecified.
Abstract. Steroid cell tumors (SCTs) (not otherwise specified (NOS)) are rare sex cord-stromal tumors of the ovary. These are associated with hormonal disturbances resulting in menstrual bleeding patterns and androgenic effects.
A review of the world literature1,2,6,7,39,40 revealed an 80% to 85% survival rate in patients with pulmonary metastases from giant cell tumor of the bone. In fact, spontaneous regression of pulmonary lesions has been reported in the literature.
For most cases, the postoperative recurrence could be observed within 24 months after the surgery. Depending on the type of surgical procedure and local presentation of the tumor, the recurrence rate of GCTB could range from 2.5% to 45% [5], [6].
Giant Cell tumors (GCT) are benign tumors with potential for aggressive behavior and capacity to metastasize. Although rarely lethal, benign bone tumors may be associated with a substantial disturbance of the local bony architecture that can be particularly troublesome in peri-articular locations.
Giant cells are formed by fusion of various cells such as macrophage, epithelioid cells, monocytes, etc., These are multi-nucleated,[1] large in size, and most of the times present at the site of chronic inflammation and other granulomatous conditions.
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere.
The 2022 edition of ICD-10-CM D48.1 became effective on October 1, 2021.
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as D48.1. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
Other locations have been reported, such as wrist, ankle, knee, hip, elbow. Intra-articular localized tenosynovial giant cell tumors are most frequent in the knee.
A ring or halo of intracytoplasmic hemosiderin may be present around the periphery of these large histiocytoid cells
Some cases show a paucity of giant cells, which is why it is best to know the constellation of histologic features aside from the presence of giant cells in order to make the diagnosis in giant cell poor cases. Tenosynovial giant cell tumor, localized type, is the second most common tumor of the hand (ganglion cyst is most common). It shows a predilection for females (F:M=2:1). The tumors are usually well circumscribed. They may recur but simple excision is curative the majority of the time. Some patients report a history of trauma but not all.
727.02 is a legacy non-billable code used to specify a medical diagnosis of giant cell tumor of tendon sheath. This code was replaced on September 30, 2015 by its ICD-10 equivalent.
Type 1 Excludes Notes - A type 1 Excludes note is a pure excludes note. It means "NOT CODED HERE!" An Excludes1 note indicates that the code excluded should never be used at the same time as the code above the Excludes1 note. An Excludes1 is used when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
TGCT tumors grow due to genetic overexpression of colony stimulating factor 1. This causes colony-stimulating factor-1 receptor (CSF1R) cells to accumulate in the joint tissue.
The disorder is difficult to identify and is often not diagnosed for years due to nonspecific symptoms or a general paucity of symptoms. TGCT cases are often misdiagnosed as osteoarthritis, localized trauma, sports injuries, xanthomas, or other conditions.
Common symptoms of TGCT include swelling, pain, stiffness and reduced mobility in the affected joint or limb. : 102 This group of tumors can be divided into different subsets according to their site, growth pattern, and prognosis. : 361 Localized TGCT is sometimes referred to as giant cell tumor of the tendon sheath; : 100 diffuse TGCT is also called pigmented villonodular synovitis (PVNS). : 102
Tenosynovial giant cell tumor ( TGCT) is a group of rare, typically non-malignant tumors of the joints . TGCT tumors often develop from the lining of joints (also known as synovial tissue).:100:245. Common symptoms of TGCT include swelling, pain, stiffness and reduced mobility in the affected joint or limb.:102 .
Diffuse TGCT occurs less frequently and is locally aggressive (in some cases, tumors may infiltrate surrounding soft tissue ). : 245 : 1 : 102 : 1 It most commonly affects people under 40 years old, though the age of occurrence varies. : 102 Diffuse TGCT may occur inside a joint (intra-articular) or outside of a joint (extra-articular). Intra-articular tumors typically occur in the knee (approximately 75% of cases) and hip (approximately 15% of cases). : 102 Extra-articular tumors are usually found in the knee, thigh, and foot. : 101 Symptoms include swelling, pain, sensitivity, and/or limited range of motion. : 102 The rate of reoccurrence is estimated to be 18-46% for intra-articular tumors and 33-50% for extra-articular tumors. : 103 : 1
Surgery has been the most common form of treatment for both localized:101:361 and diffuse TGCT.:103:361:1 After surgery, patients may receive physical therapy in order to help rehabilitate affected joints.
Classification for TGCT encompasses two subtypes that can be divided according to site – within a joint (intra-articular) or outside of the joint (extra-articular) – and growth pattern (localized or diffuse) of the tumor (s). : 100 : 361 Localized and diffuse subsets of TGCT differ in their prognosis, clinical presentation, and biological behavior, but share a similar manner of disease development. : 100
ICD-9-CM 727.02 is a billable medical code that can be used to indicate a diagnosis on a reimbursement claim, however, 727.02 should only be used for claims with a date of service on or before September 30, 2015. For claims with a date of service on or after October 1, 2015, use an equivalent ICD-10-CM code (or codes).
A tumor usually arising in the synovium of joints, bursa or tendon sheath. It is characterized by the presence of mononuclear cells, multinucleated osteoclast-like giant cells, hemosiderin-laden macrophages, foam cells, and an inflammatory infiltrate. According to the growth pattern, it is classified as localized or diffuse